BRPI1012971A2 - proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central - Google Patents

proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central

Info

Publication number
BRPI1012971A2
BRPI1012971A2 BRPI1012971A BRPI1012971A BRPI1012971A2 BR PI1012971 A2 BRPI1012971 A2 BR PI1012971A2 BR PI1012971 A BRPI1012971 A BR PI1012971A BR PI1012971 A BRPI1012971 A BR PI1012971A BR PI1012971 A2 BRPI1012971 A2 BR PI1012971A2
Authority
BR
Brazil
Prior art keywords
gdnf
bdnf
application
nervous system
fusion proteins
Prior art date
Application number
BRPI1012971A
Other languages
English (en)
Portuguese (pt)
Inventor
Boivin Dominique
Castaigne Jean-Paul
Demeule Michel
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of BRPI1012971A2 publication Critical patent/BRPI1012971A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1012971A 2009-06-11 2010-06-11 proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central BRPI1012971A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18624609P 2009-06-11 2009-06-11
PCT/CA2010/000889 WO2010142035A1 (en) 2009-06-11 2010-06-11 Fusion proteins for delivery of gdnf and bdnf to the central nervous system

Publications (1)

Publication Number Publication Date
BRPI1012971A2 true BRPI1012971A2 (pt) 2018-01-16

Family

ID=43308346

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012971A BRPI1012971A2 (pt) 2009-06-11 2010-06-11 proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central

Country Status (9)

Country Link
US (1) US20120196803A1 (enExample)
EP (1) EP2440581A4 (enExample)
JP (1) JP2012529272A (enExample)
CN (2) CN103819564A (enExample)
AU (1) AU2010258052A1 (enExample)
BR (1) BRPI1012971A2 (enExample)
CA (1) CA2764777A1 (enExample)
MX (1) MX2011013258A (enExample)
WO (1) WO2010142035A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
WO2007009229A1 (en) 2005-07-15 2007-01-25 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
WO2011153642A1 (en) * 2010-06-10 2011-12-15 Angiochem Inc. Leptin and leptin analog conjugates and fusion proteins and uses thereof
MX2013000250A (es) * 2010-07-02 2013-10-28 Angiochem Inc Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
JP6234331B2 (ja) * 2014-06-13 2017-11-22 森永乳業株式会社 統合失調症治療剤
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
JP7000349B2 (ja) 2016-05-13 2022-02-04 インスティテュート デ メディシナ モレキュラー ジョアオ ロボ アントゥネス Ilc3細胞に関連する疾患を処置する方法
AU2017357931B2 (en) 2016-11-10 2024-12-05 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
CN107141354A (zh) * 2017-05-05 2017-09-08 李斯文 一种融合蛋白及光敏剂复合物及其制备方法和应用
WO2021015584A1 (ko) * 2019-07-24 2021-01-28 주식회사 에스엘바이젠 불사화된 줄기세포주의 제조 방법 및 이의 용도
JP2024522938A (ja) 2021-06-03 2024-06-21 フンダサン デー.アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳-脂肪回路を介してilc2および肥満度を制御する神経-間葉単位
CN116270429B (zh) * 2023-02-17 2025-06-10 山东省药学科学院 一种鼻黏膜给药的抗抑郁制剂及其制备方法和应用
CN120077136A (zh) * 2023-09-28 2025-05-30 广州必贝特医药股份有限公司 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0520032A2 (pt) * 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
AU2008255556B2 (en) * 2007-05-29 2014-08-07 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8802631B2 (en) * 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (en) * 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns

Also Published As

Publication number Publication date
EP2440581A4 (en) 2013-03-27
CA2764777A1 (en) 2010-12-16
AU2010258052A1 (en) 2012-01-12
US20120196803A1 (en) 2012-08-02
WO2010142035A1 (en) 2010-12-16
EP2440581A1 (en) 2012-04-18
CN102459348A (zh) 2012-05-16
JP2012529272A (ja) 2012-11-22
CN103819564A (zh) 2014-05-28
MX2011013258A (es) 2012-02-28

Similar Documents

Publication Publication Date Title
BRPI1012971A2 (pt) proteínas de fusão para aplicação de gdnf e bdnf ao sistema nervoso central
BRPI1007004A2 (pt) sistema de iluminação, e, aparelho de estereolitografia
BRPI0913526A2 (pt) sistema de aquecimento
EE01079U1 (et) Territooriumi ja selle perimeetri j„lgimise ssteem
BRPI1006922A2 (pt) sistema para descarte de medicação
BRPI0912144A2 (pt) configuração de sistema de infusão
BR112012008074A2 (pt) derivados de piridina e pirazina como moduladores de proteína quinase
BRPI1012304A2 (pt) sistema para auxílio de subida
BRPI0917867A2 (pt) método e sistema para formar estruturas reticuladas de compósito de suporte
ES2864688T8 (es) Sistema de ablación
LT2414015T (lt) Laringoskopas ir sistema
BRPI1009247A2 (pt) sistema de comando de aeronave, e, aeronave
BR112012002092A2 (pt) sistema de dessalinização e metodo de dessalinização
BR112015006428A2 (pt) sistema aperfeiçoados de registro de rolos e estruturas associadas
BR112013010183A2 (pt) sistema e método para soldador com funcionalidade de solicitação de ajuda
BR112012000444A2 (pt) sistema de dessalinização e método de dessalinização
BR112013012346A2 (pt) sistema de filtração
BRPI1010639A2 (pt) sistema farmacêutico para distribuição transmembrana
BRPI0814521A2 (pt) Sistema de desidratação e método de desidratação
BRPI0820008A2 (pt) Sistema e método para produção de grânulos
BRPI0919749A2 (pt) método para embalagem de cigarro e sistema de embalagem de cigarro
BRPI0911586A2 (pt) sistema e método de broadcast supereconômico
BR112013033525A2 (pt) sistema e método de aquecedor flashline
IT1398480B1 (it) Sistema microfluidico
BRPI1009607A2 (pt) dispositivo de iluminação, dispositivo de conexão e sistema de iluminação

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 17/00 (2006.01), A61K 38/16 (2006.0

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]